PNV
data caveat$724MCF+
PolyNovo
Medical Devices · Wound care
NovoSorb biodegradable polymer technology for wound treatment
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Dec 2025 4C(5mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$93.2M
Dec 2025 4C
Runway
CF+Cash Flow Positive
Based on Dec 2025 4C
Market Cap
$724M
Burn Rate
—
Dec 2025 4C
Shares Outstanding
691M
Pipeline Assets
2
3M Price
PNV.ASX$1.040+10.6% 3M
Low $0.880High $1.270
Pipeline Assets (2)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
6 transactionsLast 90dNo Activity
Buys0-6 vs prior
Sells0
warning3 directors bought within 30 days (02-24 – 03-12) — $520k total
Catalysts (5)· 3 upcoming · 2 past
NovoSorb BTM US revenue growth
OverdueConfirmedremoveMed30 Apr 2026
SpeculativeremoveMed30 May 2026
NovoSorb MTX hernia trial update
UpcomingExpectedremoveMed31 Aug 2026
2 past catalysts
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High98/100
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.
What drove these scores · rolling 2yr
arrow_drop_up
Cash-flow positive — 7/7 quarters with positive operating cash flow
arrow_drop_up
Revenue growing — Customer receipts trending up
arrow_drop_up
Cash position improving — Cash balance growing
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(2)
1 activeClinicalTrials.gov ↗
NAActive Not RecruitingEnrollment stale · 1724d
NovoSorb BTMStandard of Care
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
Burns
RandomizedOpen Label18 Years – 75 Years
Primary endpoint Proportion of study lesions in both groups with complete wound closure after skin grafting
ENROL150
no manual snapshots — enter via record_enrollment.py